Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Cash Flow (2016 - 2025)

Fennec Pharmaceuticals' Net Cash Flow history spans 15 years, with the latest figure at $14.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 208.44% year-over-year to $14.8 million, compared with a TTM value of $10.2 million through Dec 2025, down 24.03%, and an annual FY2025 reading of $10.2 million, down 24.03% over the prior year.
  • Net Cash Flow for Q4 2025 was $14.8 million at Fennec Pharmaceuticals, up from $3.2 million in the prior quarter.
  • The five-year high for Net Cash Flow was $37.9 million in Q1 2024, with the low at -$13.7 million in Q4 2024.
  • Average Net Cash Flow over 5 years is $511631.6, with a median of -$3.3 million recorded in 2022.
  • Biggest YoY gain for Net Cash Flow was 804.22% in 2024; the steepest drop was 1673.1% in 2024.
  • Tracing FENC's Net Cash Flow over 5 years: stood at -$3.0 million in 2021, then plummeted by 102.1% to -$6.0 million in 2022, then skyrocketed by 114.55% to $870000.0 in 2023, then tumbled by 1673.1% to -$13.7 million in 2024, then skyrocketed by 208.44% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Net Cash Flow are $14.8 million (Q4 2025), $3.2 million (Q3 2025), and -$4.0 million (Q2 2025).